Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT516 + avelumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FT516 + avelumab is an investigational **combination therapy** comprised of FT516, an engineered “off-the-shelf” natural killer (NK) cell product derived from genetically modified human induced pluripotent stem cells (iPSC), and avelumab, a fully human IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1). FT516 has enhanced expression of high-affinity CD16a and resistance to ADAM17 cleavage to increase NK cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab acts as a PD-L1 checkpoint inhibitor and enables further ADCC through engagement of immune effector cells. The combination is designed to synergistically target and eliminate cancer cells via both immune checkpoint blockade and boosted NK cell activity, particularly in advanced solid tumors[1][5][6].
- Other names
- FT516 + avelumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on FT516 + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT516 + avelumab.